Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks.

BACKGROUND The aim of this study was to assess the activity and toxicity of primary carboplatin-based chemoradiotherapy (CarboRT) and to compare CarboRT with cisplatin-based chemoradiotherapy (CisRT) in patients with locally advanced cervical cancer and poor general condition. PATIENTS AND METHODS Fifty-one locally advanced cervical cancer patients with morbidity risks were prospectively enrolled between January 2007 and April 2010. Eligible patients received weekly intravenous CarboRT with carboplatin 100 mg/m2, and a comparison was made with a historical patient group that received weekly CisRT with cisplatin 40 mg/m2. RESULTS Median follow-up was 36 months (range: 4-66 months) in the CarboRT group and 53 months (range: 4-121 months) in the CisRT group. Compared with the historical CisRT group, the CarboRT group showed no statistically significant differences in recurrence (hazard ratio [HR], 1.21; 95% confidence interval [CI], 0.52-2.81) and survival (HR, 1.80; 95% CI, 0.49-6.54). The mean numbers of received cycles of CarboRT and CisRT were 7.5 ± 1.4 and 6.0 ± 1.8, respectively (p < .001). The rates of grade 3-4 toxicity were similar in the two groups. CONCLUSIONS CarboRT was better tolerated than CisRT without compromising tumor response and survival in patients with locally advanced cervical cancer and poor general condition.

[1]  D. Alberts,et al.  Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. , 2010, The Cochrane database of systematic reviews.

[2]  Young-Tak Kim.  Current status of cervical cancer and HPV infection in Korea. , 2009, Journal of gynecologic oncology.

[3]  D. Alberts,et al.  Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Keum,et al.  Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors. , 2007, Gynecologic oncology.

[5]  C. Khorprasert,et al.  A randomized phase III trial of concurrent chemoradiotherapy in locally advanced cervical cancer: preliminary results. , 2007, Gynecologic oncology.

[6]  P. Rose,et al.  Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. , 2004, Gynecologic oncology.

[7]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Dueñas-González,et al.  A phase I study of carboplatin concurrent with radiation in FIGO stage IIIB cervix uteri carcinoma. , 2003, International journal of radiation oncology, biology, physics.

[9]  R. Higgins,et al.  Concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer. , 2003, Gynecologic Oncology.

[10]  Nilendu Gupta,et al.  The American Brachytherapy Society recommendations for low-dose-rate brachytherapy for carcinoma of the cervix. , 2001, International journal of radiation oncology, biology, physics.

[11]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[12]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[13]  B N Bundy,et al.  Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  B N Bundy,et al.  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. , 1999, The New England journal of medicine.

[15]  P J Eifel,et al.  Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. , 1999, The New England journal of medicine.

[16]  B N Bundy,et al.  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. , 1999, The New England journal of medicine.

[17]  E. Sartori,et al.  Continuous infusion of carboplatin during conventional radiotherapy treatment in advanced squamous carcinoma of the cervix uteri IIB-IIIB (UICC). A phase I/II and pharmacokinetic study. , 1997, American journal of clinical oncology.

[18]  B. Corn,et al.  Phase I/II study of concomitant irradiation and carboplatin for locally advanced carcinoma of the uterine cervix: an interim report. , 1996, American journal of clinical oncology.

[19]  R. Grenman,et al.  Carboplatin-radiation interaction in squamous cell carcinoma cell lines. , 1992, Archives of otolaryngology--head & neck surgery.

[20]  R. Crooijmans,et al.  Effectiveness in inhibition of recovery of cell survival by cisplatin and carboplatin: influence of treatment sequence. , 1991, International journal of radiation oncology, biology, physics.

[21]  F. Muggia.  Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin. , 1989, Seminars in oncology.